Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AC Immune SAACIU · Entity 6075 | Director · Chief Executive Officer | May 15, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AC Immune SA
Report date May 15, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common ShareSEC Table I · non-derivative | Direct | 3,820,288 |
Reported balance
After 2026-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-15 · Sale · Disposed 10,000 · Balance 3,820,288 F1: The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Includes 1,921,005 common shares underlying outstanding restricted share units. |
| Common ShareSEC Table I · non-derivative | IndirectBy spouse | 14,000 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: Includes 1,921,005 common shares underlying outstanding restricted share units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2026 Filed May 18, 2026 20:25 UTC | AC Immune SA ACIU · Entity 6075 | SaleCommon Share | 10,000 | $2.79 | $27,935.00 |
DisclosureSEC source: 0001651625-26-000007 · primary_doc.xml · nonDerivative · entry 1 Pfeifer Andrea · CIK 0001697107 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,820,288 F1 · price: The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 1,921,005 common shares underlying outstanding restricted share units. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 16:39 UTC Amendment | AC Immune SA ACIU · Entity 6075 | SaleShare | 10,000 | $3.14 | $31,425.00 |
DisclosureSEC source: 0001651625-26-000006 · primary_doc.xml · nonDerivative · entry 1 Pfeifer Andrea · CIK 0001697107 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,830,288 F1 · kind: This Form 4/A amends the Form 4 filed on April 16, 2026, inadvertently reporting in column 3 a purchase of 10,000 shares on behalf of the reporting person. This amendment corrects that filing to reflect that the reporting person sold 10,000 shares. F2 · price: The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.19, inclusive. F3 · balance_after: Includes 1,921,005 common shares underlying outstanding restricted share units. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 15:10 UTC | AC Immune SA ACIU · Entity 6075 | PurchaseShare | 10,000 | $3.14 | $31,425.00 |
DisclosureSEC source: 0001651625-26-000005 · primary_doc.xml · nonDerivative · entry 1 Pfeifer Andrea · CIK 0001697107 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,830,288 F2 · price: The price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.05 to $3.19, inclusive. F1 · balance_after: Includes 1,921,005 common shares underlying outstanding restricted share units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.